Madri­gal 'en­cour­aged' by ear­ly launch progress of land­mark NASH drug

Last year
Pharma

House Over­sight chair press­es FDA on Chi­na amid grow­ing ten­sions

Last year
China
FDA+

Ex­clu­sive: En­gi­neered B cell ther­a­py start­up Walk­ing Fish shuts down

Last year
People
Startups

An­titrust, AI and Alzheimer’s: Join us in New York next week

Last year
Editor's note

How in­sur­ance up­start Align­ment kept med­ical costs in check while Medicare Ad­van­tage plans strug­gled

Last year
Health Tech

From the ed­i­tor: Our fi­nal edi­tion of End­points Mar­ket­ingRx

Last year
Editor's note
Marketing

Lykos’ MD­MA ther­a­py to go be­fore FDA com­mit­tee; GSK ex­pands work with BioVer­sys

Last year
News Briefing

Lil­ly gets June ad­comm for Alzheimer's drug do­nanemab, fol­low­ing ear­li­er de­lay

Last year
FDA+

Lab­Cen­tral helped cre­ate 6,300 jobs and 19 IPOs. Amid a slump, de­mand for lab space has slowed

Last year
Startups

As dig­i­tal health uni­corns are pres­sured to do more with less, Tran­scar­ent gets a fresh $126M

Last year
Startups
Health Tech

Ex­clu­sive: Feng Zhang CRISPR start­up gath­ers patents, lock­ing up rights to fam­i­ly of edit­ing tech

Last year
Deals
R&D

Lon­nie Moul­der's Zenas clos­es a $200M Se­ries C to broad­en lead drug's au­toim­mune po­ten­tial

Last year
Financing

Flag­ship com­mits $50M to new start­up that scours vi­ral pro­teins for new drugs

Last year
Financing
Startups

Memo Ther­a­peu­tics re­fu­els with $22M to ex­pand tri­al for in­fec­tion-fight­ing an­ti­body in kid­ney trans­plant re­cip­i­ents

Last year
Financing

Ver­tex touts Cas­gevy sick­le cell launch as blue­bird makes progress with ri­val Lyf­ge­nia

Last year
Pharma
Cell/Gene Tx

Il­lu­mi­na takes a step to­ward spin­ning off Grail, though keeps op­tion open for sale

Last year
Deals
Diagnostics

UPenn and Stan­ford analy­sis finds no sec­ondary can­cer cas­es di­rect­ly due to CAR-T

Last year
R&D
Cell/Gene Tx

Sen. Cas­sidy calls on Biden to do bet­ter at shar­ing H5N1 bird flu in­for­ma­tion

Last year
Pharma
FDA+

In­dus­try groups cri­tique new guid­ance for Medicare drug price ne­go­ti­a­tions in 2027

Last year
Pharma
FDA+

ADC Ther­a­peu­tics re­veals topline Zyn­lon­ta da­ta, $105M stock of­fer­ing

Last year
Financing
R&D

Re­mod­el­ing REMS: FDA kicks off guid­ance se­ries with draft on new frame­work

Last year
FDA+

J&J re­ports lat­est da­ta on Balver­sa-based ‘pret­zel’ ther­a­py for blad­der can­cer

Last year
R&D

Gates, No­vo Nordisk, Well­come foun­da­tions put $300M in glob­al health; BioN­Tech stops prostate can­cer study

Last year
News Briefing

As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Last year
Financing
Startups
First page Previous page 161162163164165166167 Next page Last page
A service from the Financial Times